GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin.
about
Synthesis, structure and antibacterial activity of potent DNA gyrase inhibitors: N'-benzoyl-3-(4-bromophenyl)-1H-pyrazole-5-carbohydrazide derivativesBrachyspira (Serpulina) hyodysenteriae gyrB mutants and interstrain transfer of coumermycin A(1) resistanceMutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.Mutations in Bartonella bacilliformis gyrB confer resistance to coumermycin A1.Exploiting bacterial DNA gyrase as a drug target: current state and perspectives.Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus.In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class.Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance.Resistance genes of aminocoumarin producers: two type II topoisomerase genes confer resistance against coumermycin A1 and clorobiocinIn vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteriaDual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds
P2860
Q28534970-52F4DB7F-9C94-44CA-8E79-F762F7B00FF2Q30988207-C5925255-2200-45DC-BA13-85939FED4C6BQ33690598-7660D753-CEFA-4F5A-9273-48F674B41A8FQ33701326-93B7C9FB-FD57-43A4-865A-160A5F9547C0Q34214929-E44D7DD1-77C9-418D-BC47-51B9FC317126Q34446438-F71F133E-B465-48E3-997F-90DED9FD4F80Q34510396-7E59103E-D7A9-4F37-B4DF-77D9CEE79D95Q37335706-31DC31A9-34C5-4875-AC0C-7CAEC2C2CAE6Q39731838-8A08668F-55B6-48AA-9E33-833230F18458Q39731985-5A7A748B-2D0D-4BD6-86F2-CCA538ABE4BCQ41668866-3DADC35D-B229-40B4-8C8C-3536F8B2FA0EQ41822811-AB160964-B851-4D47-9BFB-58D4F971B179
P2860
GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
GyrB mutations in Staphylococc ...... , coumermycin, and novobiocin.
@en
GyrB mutations in Staphylococc ...... , coumermycin, and novobiocin.
@nl
type
label
GyrB mutations in Staphylococc ...... , coumermycin, and novobiocin.
@en
GyrB mutations in Staphylococc ...... , coumermycin, and novobiocin.
@nl
prefLabel
GyrB mutations in Staphylococc ...... , coumermycin, and novobiocin.
@en
GyrB mutations in Staphylococc ...... , coumermycin, and novobiocin.
@nl
P2093
P2860
P356
P1476
GyrB mutations in Staphylococc ...... e, coumermycin, and novobiocin
@en
P2093
Wohlgensinger B
P2860
P304
P356
10.1128/AAC.40.4.1060
P407
P577
1996-04-01T00:00:00Z